Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$133.0MMiss by $7.9M
EPS$0.05Beat by $0.15
Revenue estimate$140.9M
EPS estimate-$0.10

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$178.1M
EPS estimate-$0.53

Financials

Q3 2025

Income statement

See full
Revenue$133.0M+47.2%
Operating income$2.6M+121%
Net income$2.9M+120%
EPS (diluted)$0.05+117%

Balance sheet

See full
Cash & equivalents$230.1M+17.5%
Total debt$9.4M-5.9%
Total equity$292.0M+25.9%
Total assets$785.1M+17.6%

Cash flow

See full
Operating cash flow$39.7M+896%
CapEx$187.0K+3.3%
Free cash flow$39.5M+938%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.68B+99.9%
Enterprise value$3.46B+109%
P/S7.8×+1.8×

Profitability

See full
Operating margin-8.9%-3.7pp
Net margin-8.8%-3.7pp

Returns & leverage

See full
Return on equity-15.8%-5.9pp
Debt / equity0×0.0×
Current ratio3.3×0.0×

Segments

By product

See full
Livmarli$92.2M+56.0%
Bile Acid Medicines$40.8M+30.8%

FAQ

When did Mirum Pharmaceuticals, Inc. report Q3 2025 earnings?
Mirum Pharmaceuticals, Inc. (MIRM) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Mirum Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Mirum Pharmaceuticals, Inc. reported revenue of $133.0M and eps of $0.05 for Q3 2025.
Did Mirum Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $140.9M by $7.9M. EPS beat the consensus estimate of $-0.10 by $0.15.
How did Mirum Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 47.2% from $90.4M a year earlier.
Where can I find Mirum Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001759425-25-000053) and the 10-Q periodic report (0001759425-25-000054) directly on SEC EDGAR. The filing index links above go to sec.gov.